The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,258,719 Project Grant to The Children's Hospital Corporation, doing business as Boston Children's Hospital, to conduct research on "Melanoma Chemoprevention via Neuropilin-2 Axis Blockade." The grant, which spans from July 15, 2024, to July 14, 2027, will support Boston Children's Hospital's investigations into developing new therapeutic approaches to prevent and treat melanoma, a form of skin cancer. As a prominent pediatric teaching hospital and research center affiliated with Harvard Medical School, Boston Children's Hospital has a track record of conducting biomedical research and clinical trials on various health conditions affecting children and the broader population.
Generated 3/4/25, 8:13 AM